Cargando…
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and new treatment strategies are needed. Ovarian cancer tumors are known to host an immunosuppressive microenvironment. This suppression may be reversible via activation of th...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666910/ https://www.ncbi.nlm.nih.gov/pubmed/23723721 http://dx.doi.org/10.2147/CPAA.S40401 |
_version_ | 1782271406781759488 |
---|---|
author | Brueseke, Taylor J Tewari, Krishnansu S |
author_facet | Brueseke, Taylor J Tewari, Krishnansu S |
author_sort | Brueseke, Taylor J |
collection | PubMed |
description | Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and new treatment strategies are needed. Ovarian cancer tumors are known to host an immunosuppressive microenvironment. This suppression may be reversible via activation of the innate immune response. Toll-like receptor 8 activates innate immunity while simultaneously inhibiting the effects of regulatory T cells within the ovarian cancer tumors. VTX-2337 is a novel small molecule ligand of Toll-like receptor 8 and is currently the subject of a Phase II randomized, double-blind, placebo-controlled trial Gynecologic Oncology Group (GOG)-3003 for patients with recurrent platinum-resistant ovarian cancer. We look forward to the results of this trial as support for the paradigm of process therapy in the treatment of ovarian cancer. |
format | Online Article Text |
id | pubmed-3666910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-36669102013-05-30 Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma Brueseke, Taylor J Tewari, Krishnansu S Clin Pharmacol Review Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and new treatment strategies are needed. Ovarian cancer tumors are known to host an immunosuppressive microenvironment. This suppression may be reversible via activation of the innate immune response. Toll-like receptor 8 activates innate immunity while simultaneously inhibiting the effects of regulatory T cells within the ovarian cancer tumors. VTX-2337 is a novel small molecule ligand of Toll-like receptor 8 and is currently the subject of a Phase II randomized, double-blind, placebo-controlled trial Gynecologic Oncology Group (GOG)-3003 for patients with recurrent platinum-resistant ovarian cancer. We look forward to the results of this trial as support for the paradigm of process therapy in the treatment of ovarian cancer. Dove Medical Press 2013-05-23 /pmc/articles/PMC3666910/ /pubmed/23723721 http://dx.doi.org/10.2147/CPAA.S40401 Text en © 2013 Brueseke and Tewari, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Brueseke, Taylor J Tewari, Krishnansu S Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma |
title | Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian
carcinoma |
title_full | Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian
carcinoma |
title_fullStr | Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian
carcinoma |
title_full_unstemmed | Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian
carcinoma |
title_short | Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian
carcinoma |
title_sort | toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian
carcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666910/ https://www.ncbi.nlm.nih.gov/pubmed/23723721 http://dx.doi.org/10.2147/CPAA.S40401 |
work_keys_str_mv | AT brueseketaylorj tolllikereceptor8augmentationofinnateimmunityinplatinumresistantovariancarcinoma AT tewarikrishnansus tolllikereceptor8augmentationofinnateimmunityinplatinumresistantovariancarcinoma |